ArticleMayo Clinic proceedings. Digital health2024
Beyond Atrial Fibrillation: Machine Learning Algorithm Predicts Stroke in Adult Patients With Congenital Heart Disease.
Article in Mayo Clinic proceedings. Digital health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence in Adult Congenital Heart Disease: Diagnostic and Therapeutic Applications and Future Directions.Reviews in cardiovascular medicine · 2025Review
- Clinical applications of artificial intelligence and machine learning in neurocardiology: a comprehensive review.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a robust risk prediction model for stroke and systemic embolism (SSE) in adult patients with congenital heart disease (ACHD), using artificial intelligence. Patients and Methods: Deidentified insurance claims from the Optum Labs Data Warehouse, including enrollment records and medical and pharmacy claims for commercial and Medicare Advantage enrollees, were used to identify 49,276 patients with ACHD, followed between January 1, 2009, and December 31, 2014. The group was randomly divided into development (70%) and validation (30%) cohorts. The development cohort was used to train 2 machine learning (ML) algorithms, regularized Cox regression (RegCox), and extreme gradient boosting (XGBoost) to predict SSE at 1, 2, and 5 years. The Shapley additive explanations (SHAP) model was used to identify the variables particularly driving the SSE risk. Results: Within this large and diverse cohort of patients with ACHD (mean age, 59 ± 19 years; 25,390 (51.5%) female, 35,766 [77.6%]) white), 1756 (3.6%) patients experienced SSE during follow-up. In the Validation cohort, CHA Conclusion: ML models significantly outperformed the clinical risk scores in patients with ACHD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.